Cathy Eng, MD, on Anal Squamous Cell Cancer: Management Strategies
2017 Gastrointestinal Cancers Symposium
Cathy Eng, MD, of The University of Texas MD Anderson Cancer Center, discusses management approaches to anal cancer, including the current standard of care, as well as novel approaches for locally advanced and metastatic disease.
Masanori Terashima, MD, PhD, of Shizuoka Cancer Center, discusses phase III study findings evaluating bursectomy for patients with subserosal/serosal gastric cancer (Abstract 5).
Sarah E. Hoffe, MD, of the Moffitt Cancer Center, discusses the controversial role of radiation in the treatment of pancreatic cancer, recent advances in delivering short courses of high-dose stereotactic body radiation therapy, and how best to integrate this new modality in borderline and locally advanced disease.
Michael J. Overman, MD, of The University of Texas MD Anderson Cancer Center, discusses study findings on nivolumab alone or in combination with ipilimumab in patients with DNA mismatch repair–deficient/microsatellite instability high metastatic colorectal cancer (Abstract 519).
Geoffrey Ku, MD, MBA, of Memorial Sloan Kettering Cancer Center, discusses the promise of immunotherapy drugs and the search for biomarkers that will help identify patients more likely to respond, not only to these medications, but to combinations of immunotherapies, other targeted treatments, chemotherapy drugs, and radiation.
Ian Chau, MD, of the Royal Marsden Hospital, discusses the continuum of care in esophageal and gastric cancers and the multiple active lines of treatment. Routine adoption of genomic testing may lead to further refinement of current treatment and more options in the future.